Presulock 20 Tablet: Each film coated tablet contains Olmesartan Medoxomil BP 20 mg.
Not Found
Presulock is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction.
No significant drug interactions were reported in studies in which olmesartan was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)3/Mg(OH)2]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected.
Non-Steroidal Anti-inflammatory Agents including Selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-admininstration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure.
Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Colesevelam hydrochloride: Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan.
Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including olmesartan.
Olmesartan is contraindicated in patients who are hypersensitive to any component of this product. Co-administration of aliskiren with olmesartan is contraindicated.
Treatment with olmesartan was well tolerated, with an incidence of adverse events similar to placebo. The following adverse events occurred in placebo-controlled clinical trials at an incidence of more than 1% of patients treated with olmesartan, but also occurred at about the same or greater incidence in patients receiving placebo: back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis and sinusitis.
Other potentially important adverse reactions that have been reported with an incidence of greater than 0.5% are: chest pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, nausea, tachycardia, hypercholesterolemia, anthralgia, arthritis, myalgia, rash. Facial edema can rarely occur.
No known restrictions. Linolenic acid (LA), Gamma-linolenic acid (GLA), and Dihomo-gamma-linolenic acid (DGLA) are importantcomponents of human breast milk, so it is reasonable to assume that Evening Primrose Oil may be taken while nursing. According to World Health Organization (WHO), pregnant or lactating women should get 5% of their total daily caloric intake from EFAs.